Agomab Therapeutics NV

David R Epstein, a Director of Agomab Therapeutics NV, purchased 10,000 shares of common stock on October 21, 2026.

David R Epstein, a Director of Agomab Therapeutics NV, purchased 5,000 shares of common stock on October 8, 2026 for $8.90 per share.

David R Epstein, a Director of Agomab Therapeutics NV, purchased 10,000 shares of common stock on October 5, 2026.

Pierre Thadee Victor Kemula, Chief Financial Officer of Agomab Therapeutics NV, purchased 10,000 shares of common stock on October 6, 2026.

Tim Jasper Knotnerus, Chief Executive Officer and a Director of Agomab Therapeutics NV, purchased 11,000 shares of common stock on October 5, 2026.

Marino Garcia, a Director of Agomab Therapeutics NV, received 57,482 shares of common stock on September 11, 2026.

LSP 7 Cooperatieve U.A. and LSP 7 Management B.V. have disclosed a 10.6% beneficial ownership in AgomAb Therapeutics NV following an IPO and additional share purchases.

Redmile Group, LLC and Jeremy C. Green have filed a Schedule 13G reporting a 5.6% beneficial ownership stake in AgomAb Therapeutics NV.

Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 5.01% of Agomab Therapeutics NV's American Depositary Shares.

Sanofi has reported beneficial ownership of 5.71% of AgomAb Therapeutics' common shares, totaling 2,783,096 shares.

Investment firm Pontifax has filed a Schedule 13G reporting a 6.8% beneficial ownership stake in Agomab Therapeutics NV.

FMR LLC and Abigail P. Johnson have reported a 10.0% beneficial ownership stake in Agomab Therapeutics SA, totaling 4,873,680 common shares.